Global Nuclear medicine market
Global Nuclear Medicine Market to Reach USD 29.82 Billion by 2030, Driven by AI Integration and Advanced Radiopharmaceuticals
March 2026 | Pheonix Research
The Global Nuclear Medicine Market is projected to grow from USD 13.00 billion in 2025 to USD 29.82 billion by 2030, expanding at a CAGR of 18.06% during the forecast period, according to the latest analysis by Pheonix Research.
Market growth is fueled by increasing adoption of advanced imaging technologies, AI-driven radiopharmaceutical development, and rising demand for precision medicine. The growing prevalence of chronic diseases, such as cancer and cardiovascular disorders, is driving the need for non-invasive, accurate diagnostic and therapeutic solutions.
Sakshi Dubey, Analyst – Healthcare & Medical Devices at Pheonix Research, stated:
“The global nuclear medicine industry is rapidly evolving into a technology-driven, patient-centric ecosystem. AI integration, advanced radiopharmaceuticals, and hybrid imaging systems are no longer optional — they are becoming critical differentiators. Post-2025 growth will be defined by strategic investments, regulatory compliance, and innovation in diagnostics and therapy.”
Key Market Highlights:
-
North America remains the largest regional market, supported by strong regulatory frameworks, FDA approvals, and advanced healthcare infrastructure.
-
Asia-Pacific is the fastest-growing region, fueled by rising healthcare expenditure, government initiatives, and expanding access to nuclear medicine technologies in China and India.
-
Technological Integration: PET, SPECT, PET/CT, and SPECT/CT imaging systems, combined with AI-driven diagnostics, are enhancing accuracy and operational efficiency.
-
Product and Therapy Trends: Targeted radiopharmaceuticals for oncology, neurology, and cardiology applications are gaining adoption.
-
Regulatory Compliance: FDA, IAEA, and EMA approvals facilitate safe, standardized usage of diagnostic and therapeutic nuclear medicine solutions.
-
Innovation in Isotope Production: Cyclotron and nuclear reactor production technologies are improving isotope availability and supporting theranostics expansion.
The competitive landscape is moderately consolidated, with major players including Life Healthcare, Bayer AG, NorthStar Medical Radioisotopes, GE Healthcare, and Lantheus Holdings, Inc. leveraging strategic partnerships, acquisitions, and technology-driven innovation to maintain leadership. Barriers to entry remain high due to regulatory complexity, capital intensity, and specialized technical expertise.
Pheonix Research’s report provides comprehensive insights into market trends, segmentation by end user, application, product type, radiopharmaceutical type, and isotope production technology, regional dynamics, competitive benchmarking, and long-term growth opportunities within the Global Nuclear Medicine Market.
📈 For a detailed look at the full report, visit:
👉 https://www.pheonixresearch.com/healthcare/molecular-imaging-nuclear-diagnostics/market-report/global-nuclear-medicine-market/
About Pheonix Research
Pheonix Research is a global market intelligence and strategic advisory firm delivering data-driven insights across healthcare, medical devices, and other high-growth sectors. Through advanced forecasting tools and AI-backed analytics, the firm helps stakeholders identify emerging opportunities and achieve sustainable competitive advantage.
Media Contact:
Pheonix Research
Email: Media@pheonixresearch.com
Website: www.pheonixresearch.com